Here's why the CSL (ASX:CSL) share price is up 5% in a month

Here's two happenings that might explain CSL's recent gains.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The last 30 days have been good to the CSL Limited (ASX: CSL) share price.

Its gained 4.97% over the month to today, despite releasing no news to the market. In fact, the last time the ASX heard price-sensitive news from CSL was back in early May.

Right now, the CSL share price is $292.73.

Let's take a look at what's been driving it lately.

doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares

Image source: Getty Images

What's up with the CSL share price?

It's been a quiet, yet productive month on the ASX for CSL.

While it has been in and out of the news due to its contract to produce AstraZeneca's COVID-19 vaccine, the company itself hasn't announced anything.

So, it's a mystery as to why the CSL share price is gaining. Or is it? Here are two happenings that might explain why the healthcare giant's stock is surging.

Australian dollar

CSL is an Australian company, but most of its profit comes from overseas.

In financial year 2020, only 1.5% of CSL's external operating revenue came from Australia.

Most of its income came from the United States. And right now, $1 Australian is only getting US$0.73.

That means when CSL earns income in US dollars, it gets more Aussie bucks back in its pocket. Although, the company does report in US dollars, so we likely won't see the impact of the currency fluctuation in its upcoming full year report.

mRNA possibility

It's also less than a month since the federal government's approach to the market, calling for companies to submit their interest in creating mRNA vaccines, closed to new applicants.

According to reporting by ABC News, Industry Minister Christian Porter confirmed CSL has put itself forward to be considered as an mRNA vaccine manufacturer.

The anticipation of finding out who has won the federal government's favour might also be boosting the CSL share price.

Of course, CSL already makes the AstraZeneca vaccine in its Melbourne facility.

CSL share price snapshot

The month that's been has added to CSL's strong performance on the ASX.

The CSL share price is currently 2% higher than it was at the start of 2021. It has also gained 3% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »